Eli Lilly (NYSE:LLY) has partnered with India’s Cipla to market its weight-loss medication Tirzepatide under a new brand in the country.
According to the agreement announced by the companies, Lilly will produce the drug, while Cipla will handle its marketing under the name Yurpeak.
Tirzepatide is a GLP-1 receptor agonist which helps manage blood sugar levels and slow down digestion, aiding weight loss.
Yurpeak will be offered as a pre-filled injector pen that patients can use once a week, similar to Lilly’s Mounjaro Kwikpen.
Lilly launched Mounjaro in India in late March for treating diabetes and obesity, initially offering it in 2.5 mg and 5 mg vials.
The medication will come in six different dosages: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, and will be priced similarly to Mounjaro.